Lessons Learned: The Real Stories From the Road to Success
Thursday, October 24 2013
8:00 am – 10:00 am
Location: MassBio, 300 Technology Square, Cambridge
Press releases show the glamorous side of biotech – successful financing rounds, executive appointments, regulatory filings, partnerships, huge exits. It all sounds so easy: get an idea, run a few experiments, launch a company then retire to a private island in the South Pacific.
But the unexpected can be just around the corner. We’ve all heard the stories, or have we?
Come join us to hear the real story behind the story. Our panelists will discuss the challenges they have encountered on the path to success and will share some of the real world lessons learned along the way.
- Lou Arcudi, Chief Financial Officer, Treasurer, and Secretary, Idera
- Bonnie Fendrock, Co-founder, former CEO and President, Hepregen Corporation
- Carolyn Green, President & Director, Atreaon, Inc
- Indu Javeri, President & CEO, CuriRx, Inc
- Michael Koeris, Ph.D., Founder, VP Operations, Sample6
- Julie M. Donnelly, Health Care/Life Sciences Reporter, Boston Business Journal
This Forum is presented by the Drug Discovery, Safety, Environmental & Facility Operations, Legal & Regulatory, and Business Development & Finance Forum Working Groups.
Louis J. Arcudi, III, MBA, Senior Vice President of Operations, Chief Financial Officer, Treasurer, and Secretary, Idera
Mr. Arcudi joined the Company in 2007 as Chief Financial Officer. From 2003-2007, Mr. Arcudi served as Vice President of Finance and Administration and Treasurer for Peptimmune, Inc. and was responsible for all financial business and operations. Prior to joining Peptimmune, Mr. Arcudi was Senior Director of Finance and Administration at Genzyme Molecular Oncology Corporation from 2000-2003 and Director of Finance Business Planning and Operations International at Genzyme Corporation from 1998-2000. Prior to joining Genzyme, he held finance positions with increasing levels of responsibility at Cognex Corporation, Millipore Corporation and General Motors Corporation.
Mr. Arcudi received a Master of Business Administration from Bryant College and a Bachelor of Science Degree in accounting and information systems from the University of Southern New Hampshire.
Julie M. Donnelly, Health Care/Life Sciences Reporter, Boston Business Journal
Julie Donnelly is the health care reporter for the Boston Business Journal. She particularly enjoys covering orphan and rare diseases. She has 15 years of experience in radio, television, newspaper and online reporting. Her work has been recognized by the Associated Press, the Radio and TV News Directors Association, the Society of Professional Journalists and the Society of American Business Editors and Writers.
Bernadette “Bonnie” C. Fendrock, Co-founder, former CEO and President, Hepregen Corporation
Ms. Fendrock is co-founder, and former President and CEO of Hepregen Corporation, an MIT spin-out based on Professor Sangeeta Bhatia’s bioengineered technology. Hepregen is a commercial stage company providing services and products that will transform safety screening and mechanistic understanding of drugs in preclinical development. Ms. Fendrock raised a $5M Series A venture round in 2008 and built Hepregen from an MIT lab concept into a $2M commercial operation by the end of 2011. Hepregen was the recipient of more than $3M in federal and state grants including a highly competitive grant from the Mass Life Sciences Center. In 2012 Ms. Fendrock was honored along with other innovation leaders as one of the Mass High Tech ‘Women to Watch’.
In her 25 years of life science industry experience, Ms. Fendrock has worked in high growth, entrepreneurial environments where rapid and efficient execution is at a premium. Her technology experience base includes biotherapeutics, combination medical devices, and bioengineered tools.
Ms. Fendrock was Vice President at Genzyme Corporation. At Genzyme, Ms. Fendrock started in Corporate Development and then moved to the BioSurgery business, where she was responsible for growing the business from the clinic to commercialization and worked closely with the CEO and CFO to raise a $140M secondary financing. Prior to Genzyme, Ms. Fendrock held management positions, as Director of Business Development at Somatix, Inc., a start-up gene therapy company, and Project Manager at Genetics Institute for the recombinant Factor VIII program. Prior to business school, she worked in research and product development at two newly emerging biotech companies, Integrated Genetics and Centocor.
Ms. Fendrock’s passion for the life science industry stems from cultivating innovative ideas from talented scientists to commercial reality, exciting others with a compelling story, and executing a plan with a dedicated team to create value. Ms. Fendrock is currently working as an executive advisor at InfoBionic, an emerging m-health company. Ms. Fendrock volunteers as a mentor to scientists and entrepreneurs at MIT, UMass and BU. Ms. Fendrock is a Director, Corporate Relations, for the Boston Chapter of the Healthcare Businesswomen’s Association (HBA).
Ms. Fendrock holds a B.A. degree in Molecular Biology from Wellesley College, an S.M. degree from MIT in Interdisciplinary Science, and an M.B.A. from The Wharton School of the University of Pennsylvania. Two peer reviewed scientific papers were published based on her thesis work at MIT.
Carolyn E. Green, President and Director, Atreaon, Inc.
Ms. Green is President of Atreaon, Inc., a privately held biopharmaceutical company developing novel drugs for the treatment of auto-immune and inflammatory diseases. Atreaon completed a $20 million venture capital financing to support the development of recombinant human protein analogues. Atreaon’s unique proteins are designed based on a natural anti-inflammatory human protein called Progranulin. The critical role for Progranulin in important pathophysiological processes such as inflammatory response, injury-induced tissue repair and cell and tumor growth are beginning to be understood; exploiting Progranulin’s many pathways represent an enormous potential for Atreaon. Previously, Ms. Green co-founded Logical Therapeutics, and as President she was instrumental in securing more than $45M in venture capital to support development and clinical trials for a novel family of anti-inflammatory drugs. Prior to coming to Boston, Ms. Green was the founding Director of a translational research and commercialization center at the University Of Pittsburgh School Of Medicine, where she helped to commercialize promising discoveries emanating from more than $650 million in annual research funding. Ms. Green is a member of the Board of Directors of Atreaon, Inc., The New England Women in Science Executive Club and The University of Pittsburgh & Coulter Foundation Translational Research Partnership Program.
Indu S. Javeri, Ph.D., President and CEO of CuriRx, Inc.
Indu S. Javeri, Ph.D., President and CEO of CuriRx, Inc., earned her doctorate in Chemistry from the University of Oklahoma. Dr. Javeri has 24 years of experience in the development of pharmaceuticals and biologics. The mission statement for CuriRx is: “With passion, purpose and partnerships, we transform scientific discoveries into advances in human healthcare.”
Previous to CuriRx, She was the cofounder of Formatech and served as its CEO for thirteen years. Through Formatech, Dr. Javeri had partnered with many companies to help develop their products, and formed collaborations that have led to new intellectual properties several times. At Formatech, Dr. Javeri developed a nanoparticle technology platform that targets and transforms approved pharmaceuticals as well as new chemical entities to treat patients with enhanced safety and efficacy. Under Dr. Javeri’s leadership, Formatech grew from 3 MM to 13 MM in sales and became known for producing high-quality products under cGMPs for use in manufacturing clinical trials. She is known for driving product, process, and customer service improvement while simultaneously building partnerships with key business decision makers.
Previously, Dr. Javeri has held both scientific and management positions at Genetics Institute in Andover, MA, Abbott Biotech in Needham, MA, and Cambridge Neurosciences in Cambridge, MA.
Michael Koeris, Ph.D., Founder, VP Operations, Sample6
Mike Koeris is one of the founders of Sample6, and now runs manufacturing, operations, BD and IP at Sample6. Mike co-developed Sample6's technology working with Tim Lu during his doctoral work on Systems and Synthetic Biology in the Lab of Professor Jim Collins. Prior to Sample6, Mike worked at Flagship Ventures in Cambridge as the first VentureLabs Fellow, as well as KPMG Consulting and McKinsey & in Germany. He is also visiting scholar with the Howard Hughes Medical Institute in the Biomedical Engineering Department at Boston University and the Synthetic Biology Group at MIT. Prior to receiving his doctoral degree, Mike graduated with a M.S. in Biochemistry from the Free University of Berlin, and was a recipient of the German Academic Exchange Fellowship (DAAD) to study at MIT.